A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

Advanced Multiple Myeloma Clinical Trial

Status Completed

Clinical Trial Summary

The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study. Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced Multiple Myeloma
• Multiple Myeloma
• Neoplasms, Plasma Cell

• NCT number: NCT02092922
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 2
• Start date: May 2014
• Completion date: September 5, 2017